| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Burkhard and Landis) and Central Clinical Chemistry Laboratory (Drs. Sanchez and Hochstrasser), University Hospital, Geneva, Switzerland.
Address correspondence and reprint requests to Dr. Pierre R. Burkhard, Department of Neurology, University Hospital, 1211 Geneva 14, Switzerland; e-mail: Pierre.Burkhard{at}hcuge.ch
Objective: To determine the usefulness of the 14-3-3 test in patients with dementia of various causes. Background: Recent reports have suggested that the detection of the 14-3-3 protein in the CSF of patients with Creutzfeldt–Jakob disease is a highly sensitive and specific marker of the disease that might be used as a diagnostic criterion. We examined the validity of this test when applied to a cohort of unselected patients prospectively examined for an ongoing dementing process. Methods: One hundred patients underwent an extensive neurologic examination for dementia, including a CSF 14-3-3 protein immunoblotting assay. Final clinical diagnoses were compared with the qualitative results of the test, and statistical measures of test validity were carried out. Results: We found a positive test in 14 of 100 patients, only two of whom had definite Creutzfeldt–Jakob disease. Positive results were found in patients with various degenerative dementias, including AD (4), frontotemporal dementia (2), and dementia with Lewy body (1), and in patients with vascular dementia (1), carcinomatous meningitis (1), and anoxic encephalopathy (1). In two other positive patients, the dementia could not be confidently classified. Sensitivity, specificity, and negative predictive value were fairly good, but positive predictive value was poor. Similar results were found independently of the disease duration. There was no correlation between intensity nor pattern of the 14-3-3 protein expression and diagnosis. Conclusions: The 14-3-3 test is not valid for discriminating between Creutzfeldt–Jakob disease and non-Creutzfeldt–Jakob disease in unselected patients with dementia. Positive results are found in various degenerative and secondary, prion-unrelated dementias.
This article has been cited by other articles:
|
|
 |
|
  S. Jayaratnam, A. K. L. Khoo, and D. Basic Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid Age Ageing, July 1, 2008; 37(4): 467 - 469. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Yutzy, E. Holznagel, C. Coulibaly, A. Stuke, U. Hahmann, J.-P. Deslys, G. Hunsmann, and J. Lower Time-course studies of 14-3-3 protein isoforms in cerebrospinal fluid and brain of primates after oral or intracerebral infection with bovine spongiform encephalopathy agent J. Gen. Virol., December 1, 2007; 88(12): 3469 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bersano, M. Fiorini, S. Allaria, G. Zanusso, E. Fasoli, M. Gelati, H. Monaco, G. Squintani, S. Monaco, and E. Nobile-Orazio Detection of CSF 14-3-3 protein in Guillain-Barre syndrome Neurology, December 26, 2006; 67(12): 2211 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sanchez-Juan, A. Green, A. Ladogana, N. Cuadrado-Corrales, R. Saanchez-Valle, E. Mitrovaa, K. Stoeck, T. Sklaviadis, J. Kulczycki, K. Hess, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology, August 22, 2006; 67(4): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Horvath, A. Coeytaux, P. Jallon, T. Landis, P. Temperli, and P. R. Burkhard Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease Neurology, August 23, 2005; 65(4): 650 - 651. [Full Text] [PDF]
|
|
|
|
|
|
G. Zanusso, M. Fiorini, A. Farinazzo, M. Gelati, M. D. Benedetti, S. Ferrari, A. D. Libera, S. Capaldi, H. L. Monaco, N. Rizzuto, et al. Phosphorylated 14-3-3{zeta} protein in the CSF of neuroleptic-treated patients Neurology, May 10, 2005; 64(9): 1618 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B R J Van Everbroeck, J Boons, and P Cras 14-3-3 {gamma}-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 100 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Colucci, L Roccatagliata, E Capello, E Narciso, N Latronico, M Tabaton, and G L Mancardi The 14-3-3 protein in multiple sclerosis: a marker of disease severity Multiple Sclerosis, October 1, 2004; 10(5): 477 - 481. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Castellani, M. Colucci, Z. Xie, W. Zou, C. Li, P. Parchi, S. Capellari, M. Pastore, M. H. Rahbar, S. G. Chen, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease Neurology, August 10, 2004; 63(3): 436 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Huang, S. K. Marie, J. A. Livramento, R. Chammas, and R. Nitrini 14-3-3 protein in the CSF of patients with rapidly progressive dementia Neurology, August 12, 2003; 61(3): 354 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Aksamit Cerebrospinal Fluid 14-3-3 Protein: Variability of Sporadic Creutzfeldt-Jakob Disease, Laboratory Standards, and Quantitation Arch Neurol, June 1, 2003; 60(6): 803 - 804. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Geschwind, J. Martindale, D. Miller, S. J. DeArmond, J. Uyehara-Lock, D. Gaskin, J. H. Kramer, N. M. Barbaro, and B. L. Miller Challenging the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease Arch Neurol, June 1, 2003; 60(6): 813 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peoc'h, P. Beaudry, N. Laupretre, J.-L. Laplanche, P. R. Burkhard, J.-C. Sanchez, T. Landis, and D. F. Hochstrasser CSF detection of the 14-3-3 protein in unselected patients with dementia Neurology, February 12, 2002; 58(3): 509 - 510. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
